Congratulations to Dr Sophie Kellaway who has been awarded an Early Careers Grant from Leukaemia and Myeloma Research UK. This grant will support a project entitled ‘Investigating DNA damage accumulation in Leukaemia stem cells’.
This project follows up on her work, recently published in Nature Communications, where she identified two drugs Bevacizumab/Avastin and Benralizumab/Fasenra which showed potential to be repurposed in acute myeloid leukaemia. These drugs were found to work by blocking AP-1 signalling. Blocking this pathway has the benefit of blocking cancer cell growth but could also result in altered regulation of DNA damage repair. It is therefore crucial before using these drugs in patients to understand if they are safe or whether they have the potential to cause further DNA damage, mutation and a more aggressive cancer. This funding will support answering this important question.
Read more here:
